Effects of alendronate and denosumab on glucocorticoid-induced osteoporosis by a randomized, open-labeled study

Effects of alendronate and denosumab on glucocorticoid-induced osteoporosis by a randomized, open-labeled study - Effects of alendronate and denosumab on glucocorticoid-induced osteoporosis by a randomized, open-labeled study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019642

Enrollment

Registered

2015-11-06

Start date

2015-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucocorticoid-induced osteoporosis

Interventions

alendronate 35mg/week +alfacalcidol 0.5ug/day. It continues as glucocorticoid-induced osteoporosis treatment. denosumab 60mg/6months +alfacalcidol 0.5ug/day. It continues as glucocorticoid-induced o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Guideline on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society (2014) with adaptation patients.

Exclusion criteria

Exclusion criteria: Medicine associated with the bone metabolism Pregnancy Abnormality of the serum calcium Less than 30ml/min/1.73m2 of the eGFR Severe complications such as liver, heart, renal disease Hypersentivity

Design outcomes

Primary

Measure	Time frame
Percent change in bone mineral density of the lumber spine and femoral neck	—

Secondary

Measure	Time frame
Incident vertebral fracture and non-vertebral fracture safety bone makers	—

Countries

Japan

Contacts

Public ContactTakahide Ikeda

Gifu University Graduate School of Medicine General Internal Medicine

tacahide@nifty.com058-230-6632

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026